varying concentrations (0, 3.125-100 ng/ml) of recombinant human MCP-1 (R&D Systems) was tested using the CytoSelect 96-well cell migration assay (Cell Biolabs, San Diego, CA, USA). All experiments were run a single time with each treatment group run in triplicate. After normalization for cell viability, cell culture results were expressed as fold change from the media only negative control (no CS, no LPS). One-way ANOVA with Bonferroni's post-hoc test and post-hoc linear trend were performed on cell culture results using Graphpad Prism software (La Jolla, CA, USA). Results: We found that LPS (1μg/ml) caused a significant rise in MCP-1 release (p<0.0001) from 3T3-L1 adipocytes. CS in physiologically achievable concentrations (100-200 μg/ml) produced a dose dependent reduction (p<0.01 at 100 μg/ml and p<0.001 at 200 μg/ml) of MCP-1 release from 3T3-L1 adipocytes in response to LPS. Recombinant MCP-1 (25-100 ng/ml) caused a dose dependent increase (p<0.001 at 25ng/ml and P<0.0001 at 100ng/ml) in cell migration of THP-1 monocytes. CS at the highest test concentration (200 μg/ml) had no effect on MCP-1 mediated THP-1 migration.
Background: Inflammatory process in bone marrow (BM) observed on MRI scans of rheumatoid arthritis (RA) patients (called bone marrow oedema) was shown to proceed joint destruction in RA. Our previous studies supported the concept that BM actively participate in the pathogenesis of RA by TLR triggered B cell activity (1), increased number of activated T cells and increased level of proinflammatory cytokines (2,3). Cytokines play a key role in the bone destruction of rheumatoid arthritis. Objectives: To investigate the levels of IL-21 and IL-22 in RA BM plasma and their association with bone destruction. Methods: BM samples were obtained from RA and osteoarthritis (OA) patients during total hip replacement surgery. Levels of IL-17AF, IL-21, IL-22, RANKL and cathepsin K in BM plasma were determined by specific ELISA tests. We analyzed pelvic radiographs of 22 patients with RA admitted to the NIGRR and subjected to total hip replacement. Radiographs were taken a day or two before surgery. In our study we assessed hip joint changes semi-quantitatively with the use of the proposed scoring system including primary RA (juxta-articular osteoporosis, axial joint space narrowing, inflammatory cyst presence, bony erosion) and late RA changes (axial migration of the femoral head, femoral head deformation, avascular necrosis of femoral head, femoral head subluxation). Results: We found increased levels of activated T cell associated cytokines IL-21 (924.8 pg/ml vs 688.6 pg/ml, p<0.05) and IL-22 (94.5 pg/ml vs 65.8 pg/ml, p<0.05) in BM plasma of RA patients in comparison to osteoarthritis (OA) patients. Interestingly levels of both of these cytokines strongly correlated positively with concentration of osteoclastogenesis/osteoclast activity marker RANKL and cathepsin K. Surprisingly level of IL-17AF did not correlate with RANKL or cathepsin K. Furthermore, concentration of IL-21 was statistically significantly higher in patients with more severe radiologically assessed bone destruction. Median value of concentration of IL-21 in RA patients with small bone destruction was 797.4 pg/ml, with mild bone destruction was 1037.8 pg/ml, with severe bone destruction (1079.0 pg/ml). Conclusions: Our results show an association between BM plasma levels of IL-21 and IL-22 and bone destruction, supporting the hypothesis that IL-21 and IL-22 are important pathogenic factors of this disease. Therapy targeting IL-21 and IL-22 may be of value in preventing bone erosions in patients with RA. Background: Monoclinic and triclinic calcium pyrophosphate dihydrated (mCPPD and tCPPD) and monosodium urate (MSU) crystals are responsible in human for relapsing acute arthritis. CPP and MSU crystal-triggered inflammation depends on several inflammatory mediators including interleukin (IL)-1β and prostaglandin (Pg) E2. IL-1β production is governed by NF-κB, NLRP3 inflammasome and caspase-1 activation. PgE 2 derives from arachidonic acid (AA) synthesis, which is regulated by cytosolic phospholipase A2 (cPLA 2 ), and cyclooxygenase-(COX) 2 activation. CPP crystal-induced IL-1β production is well documented, but CPP crystal-induced PgE2 production remains unclear. Objectives: To evaluate how CPP crystals induce PgE 2 production and the role of IL-1β in this process. Methods: Synthetic and pyrogen-free m-CPPD, t-CPPD and MSU crystals were used to stimulate human monocyte cell line (THP-1 cells) and primary bone marrow-derived macrophages (BMDM) of wild type (wt) and NLRP3 inflammasome deficient (nlrp3 -/-) mice. Pharmacological inhibitors were used to assess the role of oxidative stress (N-acetyl-L-cysteine, NAC) and NF-κB pathway (Bay-117085). PgE 2 and IL-1β production were quantified by ELISA, gene expression by qRT-PCR, cPLA 2 by immunoblot. NF-κB activation was assessed in THP-1 cells containing a reporter gene under control of NF-κB p65 promotor. In vivo, CPP crystal-induced PgE2 production was evaluated in the air pouch model in the presence or not of NF-κB inhibitor or NAC. Results: In vitro, m-and t-CPPD and MSU crystals rapidly induced the production of PgE 2 and IL-1β by THP-1 cells and BMDM. PgE 2 production was associated with cPLA 2 and NF-κB activation along with increased expression of COX-2 (20 fold) and its receptor EP2 and EP4 genes. While CPP crystal-induced IL-1β production was abolished in THP-1 cells by treatment with caspase-1 inhibitor and in nlrp3 -/-BMDM, CPP crystal-induced PgE 2 was not modified suggesting IL-1β-and NLRP3-independent pathways. Interestingly, CPP crystal-induced PgE 2 production was completely abrogated by NF-κB inhibitor treatment and significantly decreased by the antioxidant NAC; in both case, COX-2 gene expression was dramatically inhibited. In vivo, treatment with NAC or Bay strongly inhibited IL-1β and PgE 2 production and cellular infiltrate induced by CPP crystals. Conclusions: PgE 2 production mediated by CPP and MSU crystals is activated by NF-κB signaling, independently of NLRP3/IL-1β production axis. Moreover, ROS production, known as a NLRP3 activator in response to CPPD or MSU crystals, is also involved in the regulation of PgE 2 production. The relations between these different pathways are under investigation. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.5505 
